Nonself-donated cells (allografts) better survive implantation into the brains of immunocompetent research mice when the grafts are injected into the striatum (STR) of the brain rather than injected into the forceps minor (FM) region finds researchers at the Johns Hopkins University in Baltimore, Md., and the Mossakowski Medical Research Centre in Warsaw, Poland. In their study, all FM grafts were rejected while STR grafts accumulated and survived along the border between the striatum and the corpus callosum.
"To the best of our knowledge, this is the first demonstration that allograft survival within the central nervous system of an immunocompetent, non-immune suppressed host may be highly dependent on implantation site," said study co-author Dr. Pior Walczak of the Johns Hopkins University School of Medicine.
The study appears as an early e-publication for the journal Cell Transplantation, and is now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/pre-prints/ct0888janowski.
"This is an indicator that surgical injury may be the leading factor initiating the rejection process," the researchers said. "Thus, minimally traumatic allograft transplantation, preventing activation of the microglia and limiting foreign antigen presentation, may contribute to long-term allograft survival."
They commented that the STR grafts were transplanted closer to the ventricles than were the FM grafts, suggesting that the lateral ventricles "appear to present a favorable microenvironment." Additionally, they hypothesized that variability in cell survival may be related to the differences in immune responses that may exist between white matter and grey matter, as the FM is the largest region of white matter while the STR is a grey matter structure.
"Our observation that immunorejection depends on the graft implantation site has important ramifications," said Dr. Walczak. "It may account for the variability in allograft survival reported by different research groups."
The accumulation of transplanted cells in the 'pocket' between two natural bordering regions of the brain, with minimal disruption to tissue integrity, appears the most plausible explanation for the dramatic difference in the allograft rejection rate, they wrote.
They concluded that the impact of the topographical and anatomical characteristics of the target site for allografting should be carefully considered when designing cell therapies for neurological disorders at both the pre-clinical and clinical levels.